AKT1 and neoplasm: Ipatasertib is a novel, potent, selective small-molecule inhibitor of Akt that has been tested in combination with atezolizumab, the mAb against PD-L1 in solid tumors, including glioblastoma, with the aims of depleting the tumor microenvironment of suppressive immune cells with Akt inhibition and of making tumor cells more responsive to immune checkpoint inhibitors.